Natera Inc (NTRA)
Who owns Natera Inc (NTRA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.1% of the shares are freely tradable; institutional investors hold 95.8%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| JPMorgan Chase & Co | 9.35 | 13,386,667 | +4.1 | 03/31/2026 |
| Vanguard Group Inc | 8.59 | 12,306,424 | -0.7 | 12/31/2025 |
| T. Rowe Price Associates, Inc. | 8.51 | 12,184,876 | +12.1 | 03/31/2026 |
| BlackRock Inc | 7.46 | 10,677,338 | -1.7 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.20 | 6,008,496 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 3.94 | 5,644,695 | +0.0 | 03/31/2026 |
| Wellington Management Company LLP | 3.33 | 4,768,593 | -4.2 | 03/31/2026 |
| State Street Corp | 2.39 | 3,417,472 | +5.9 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| JPMorgan Large Cap Growth I | 4.39 | 6,282,165 | +3.3 | 04/30/2026 |
| Vanguard Total Stock Mkt Idx Inv | 2.95 | 4,222,061 | +0.2 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 29. Jul 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 1,863 | 249.38 | 464,595 |
| 28. Jul 2026 | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sell | 931 | 254.07 | 236,540 |
| 28. Jul 2026 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 1,204 | 254.07 | 305,901 |
| 28. Jul 2026 | Rabinowitz Daniel | SEC. AND CHIEF LEGAL OFFICER | Sell | 1,003 | 254.07 | 254,833 |
| 28. Jul 2026 | Chapman Steven Leonard | CEO AND PRESIDENT | Sell | 3,580 | 254.07 | 909,572 |
| 28. Jul 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 170 | 254.33 | 43,237 |
| 28. Jul 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 1,008 | 253.77 | 255,797 |
| 28. Jul 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 1,241 | 254.07 | 315,301 |
| 28. Jul 2026 | Sheena Jonathan | Director | Sell | 191 | 254.07 | 48,527 |
| 27. Jul 2026 | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sell | 782 | 260.49 | 203,704 |
| 27. Jul 2026 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 1,010 | 260.49 | 263,096 |
| 27. Jul 2026 | Rabinowitz Daniel | SEC. AND CHIEF LEGAL OFFICER | Sell | 884 | 260.49 | 230,274 |
| 27. Jul 2026 | Chapman Steven Leonard | CEO AND PRESIDENT | Sell | 2,190 | 260.49 | 570,475 |
| 27. Jul 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 782 | 260.49 | 203,704 |
| 27. Jul 2026 | Sheena Jonathan | Director | Sell | 288 | 260.49 | 75,021 |
| 27. Jul 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 1,718 | 260.49 | 447,523 |
| 15. Jul 2026 | Chapman Rowan E | Director | Sell | 135 | 274.82 | 37,101 |
| 15. Jul 2026 | Sheena Jonathan | Director | Sell | 80 | 276.02 | 22,081 |
| 15. Jul 2026 | Sheena Jonathan | Director | Sell | 180 | 274.99 | 49,497 |
| 15. Jul 2026 | Sheena Jonathan | Director | Sell | 100 | 273.68 | 27,368 |
| 15. Jul 2026 | Sheena Jonathan | Director | Sell | 390 | 273.01 | 106,473 |
| 15. Jul 2026 | Sheena Jonathan | Director | Sell | 40 | 276.38 | 11,055 |
| 15. Jul 2026 | Sheena Jonathan | Director | Sell | 170 | 275.26 | 46,795 |
| 15. Jul 2026 | Sheena Jonathan | Director | Sell | 90 | 274.26 | 24,683 |
| 15. Jul 2026 | Sheena Jonathan | Director | Sell | 450 | 273.05 | 122,871 |
| 13. Jul 2026 | Sheena Jonathan | Director | Sell | 450 | 267.72 | 120,475 |
| 13. Jul 2026 | Sheena Jonathan | Director | Sell | 400 | 265.15 | 106,060 |
| 13. Jul 2026 | Sheena Jonathan | Director | Sell | 800 | 264.29 | 211,436 |
| 13. Jul 2026 | Sheena Jonathan | Director | Sell | 500 | 268.39 | 134,194 |
| 6. Jul 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 1,000 | 280.00 | 280,000 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.